LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of “Moderate Buy” from Analysts

LivaNova PLC (NASDAQ:LIVN) has received an average rating of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $61.17.

A number of equities research analysts have recently issued reports on LIVN shares. The Goldman Sachs Group dropped their target price on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Stifel Nicolaus dropped their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 26th. Mizuho lowered their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. Finally, Barclays lowered their price target on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, March 7th.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $41.41 on Thursday. LivaNova has a one year low of $36.85 and a one year high of $64.48. The firm has a market cap of $2.25 billion, a PE ratio of 98.60 and a beta of 1.10. The firm has a fifty day moving average of $45.88 and a 200 day moving average of $49.01. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Institutional Trading of LivaNova

Several hedge funds have recently made changes to their positions in the business. Jefferies Financial Group Inc. purchased a new stake in shares of LivaNova during the fourth quarter worth approximately $4,812,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of LivaNova by 25.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 153,458 shares of the company’s stock worth $7,107,000 after buying an additional 30,718 shares during the period. Squarepoint Ops LLC increased its stake in shares of LivaNova by 74.3% during the fourth quarter. Squarepoint Ops LLC now owns 111,449 shares of the company’s stock worth $5,161,000 after buying an additional 47,494 shares during the period. Two Sigma Advisers LP increased its stake in shares of LivaNova by 148.5% during the fourth quarter. Two Sigma Advisers LP now owns 214,545 shares of the company’s stock worth $9,936,000 after buying an additional 128,200 shares during the period. Finally, Two Sigma Investments LP increased its stake in shares of LivaNova by 27.2% during the fourth quarter. Two Sigma Investments LP now owns 439,582 shares of the company’s stock worth $20,357,000 after buying an additional 93,985 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.